Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Nilotinib in CML-CP

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 19 or older~* Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase~Exclusion Criteria:~* CML with atypical BCR-ABL1 transcripts (transcripts other than e13a2 or e14a2)~* Eastern Cooperative Oncology Group performance status ≥ 3~* Cardiac abnormality including a corrected QT interval ≥ 480 milliseconds, complete left bundle branch block, permanent pacemaker implantation, congenital long QT syndrome, history of tachyarrhythmia requiring treatment, clinically significant resting bradycardia, history of acute coronary syndrome within 12 months, and decompensated congestive heart failure~* Organ dysfunction defined by total serum bilirubin levels ≥ 1.5 × the upper limit of the normal range (ULN), creatinine ≥ 1.5 × ULN, aspartate or alanine aminotransferase ≥ 2.5 × ULN, amylase or lipase ≥ 1.5 × ULN and alkaline phosphatase ≥ 2.5 × ULN not directly related to the CML~* Uncontrolled hypertension and/or diabetes~* Active and uncontrolled infection~* Major surgery within two weeks or incomplete recovery from the previous surgery~* Congenital or acquired bleeding tendency~* Impaired gastrointestinal absorption~* History of small bowel resection or bypass surgery~* History of acute pancreatitis within 12 months or chronic pancreatitis~* Concomitant administration of strong irreplaceable CYP3A4 inhibitors or inducers, QT-prolonging agents, or coumarin derivatives~* Any other uncontrolled medical conditions that would present substantial safety risks or compromise compliance with the study treatment

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Investigational arm (Type: EXPERIMENTAL): Oral nilotinib 300mg twice daily with a 12-hour interval

Based on this trial design, predict the completion outcome and termination type (if applicable).